Drugs /

interferon gamma-1b

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for interferon gamma-1b

Interferon gamma-1b has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating interferon gamma-1b, 1 is phase 2 (1 open).

CTAG1B Expression is the most frequent biomarker inclusion criterion for interferon gamma-1b clinical trials.

Mycosis fungoides, sezary syndrome, and synovial sarcoma are the most common diseases being investigated in interferon gamma-1b clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Interferon Gamma-1b
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating interferon gamma-1b and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ifn-g-1b, gamma interferon 1b, ifn-gamma 1b, interferon gamma-1b, recombinant, recombinant interferon gamma-1b, ifng-1b, interferon gamma-1b, recombinant, interferon gamma-1b, recombinant, n(sup 2)-l-methionyl-1-139-interferon gamma (human lymphocyte protein moiety reduced), actimmune, n(sup 2)-l-methionyl-1-139-interferon g, interferon gamma-1b
Drug Target(s) [2]:
IFNGR1, IFNGR2
NCIT ID [1]:
C100089

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.